Kornimate/medical-research-clean huggingface dataset:
efficacy of jessener solution versus intralesional steroid in treatment of alopecia areata

Conditions: Alopecia Areata

Summary: alopecia areata is believed to be an autoimmune disease. treatment primarily relies on intralesional and topical corticosteroids. this study was conducted to evaluate jessener solutionas a potential therapeutic modality of alopecia areataversusintralesional steroid as regards the efficacy, safety, tolerability, and patients' satisfaction.

background alopecia areata is believed to be an autoimmune disease resulting from a breach in the immune privilege of the hair follicles causing non scarring hair loss.treatment primarily relies on intralesional and topical corticosteroids.up till now, there is nouniversally proven therapy that induces and maintains remission of alopecia areata in all patients. aims the aim of study is to evaluate the efficacyof jessener solution versus intralesional steroid in treatment of alopecia areata. patients and methods the study will include 40 patients diagnosed clinically and dermoscopically as alopecia areata with more than two patches of alopecia areata were included. two treatment modalities with intralesional corticosteroid and topical jessener solutionas were performed in two randomly selected patches. three sessions were done, 3 weeks apart and were followed-up for three months. evaluation was done using mac donald hull and norris grading system , serial photographs and dermoscopic , trichoscopic examination every month will be done and patient will be score.

Eligibility criteria:
inclusion criteria: * 1.alopecia areatamultilocuolaris.2.age from18-50years old. 3.wash out period is two months. 4.ophiasis pattern alopecia areata. exclusion criteria: * age less than 12 yearsand more than 40years old. 2.patient under treatment.3.patients having another dermatological condition affecting thescalpas eczema.4.patients with psychiatric disorders.5.pregnant and lactating females.
infection prevention and control practices regarding covid-19

Conditions: COVID-19 Pandemic

Summary: background: healthcare providers, particularly nurses, are at risk of infection as part of the covid-19 epidemic chain since they assist in the disease's containment. by recognising the risk factors for infection and implementing suitable measures to reduce these risks, all reasonable efforts should be taken to control the spread of infection to them. the major aim of the present study was to determine the level of infection prevention and control practises used by primary healthcare nurses in saudi arabia during the covid-19 pandemic.


Eligibility criteria:
inclusion criteria: * male and female healthcare practitioners with at least one year of experience and who worked in all areas of primary healthcare facilities during the covid-19 epidemic. exclusion criteria: * healthcare providers that are unwilling to participate in the present study have been eliminated

Keywords: infection prevention infection control primary healthcare nurses saudi arabia
therapeutic effects of silymarin in patients with b-thalassemia major

Conditions: Beta-thalassemia Major; Iron Overload

Summary: silymarin, a flavonolignan complex isolated from silybum marianum, has a strong antioxidant, hepatoprotective and iron chelating activities. the present study has been designed to investigate the therapeutic activity of orally administered silymarin in patients with thalassemia major under conventional iron chelation therapy. a 6-month randomized, double-blind, clinical trial was conducted in 140 beta-thalassemia major patients in two well-matched groups. patients are randomized to receive a silymarin tablet (140 mg) three times a day plus conventional desferrioxamine therapy or the same therapy but a placebo tablet instead of silymarin. clinical laboratory tests of iron status and liver function are assessed at the beginning and the end of the trial.


Eligibility criteria:
inclusion criteria: * presence of major beta-thalassemia * age 12 years or older * iron overload condition (serum ferritin levels between 1000-5000 ng/ml) regular desferrioxamine administration (50 mg/kg) * continuous blood transfusions * negative crp test exclusion criteria: * hepatitis b or c infection * positive hiv test * chronic renal or heart failure * iron chelating therapy with other iron chelators

Keywords: iron overload condition regular desferrioxamine administration receiving continuous blood transfusions
effect of communication board on functional communication of children with cerebral palsy

Conditions: Cerebral Palsy (CP)

Summary: my aim of the research is to compare the effect of traditional therapy with the aac device and identify if the aac device is more effective for cp children than traditional therapy.


Eligibility criteria:
inclusion criteria: * children of both genders with cerebral palsy age group 8 years-12 years * children with cerebral palsy having mild to moderate cognitive impairment and communication impairment * children with comorbid conditions (epilepsy, microcephalia) * children with physical abilities of functional pointing, one step command * following, vocalization, and imitation. exclusion criteria: * children with comorbid conditions (visual impairment, hearing impairment
safety and long-term effectiveness of high frequency repetitive transcranial magnetic stimulation of stroke (raicup)

Conditions: Nervous System Diseases; Stroke; Cerebrovascular Disorders; Brain Infarction; Brain Ischemia

Summary: the aim of the study is to determine if 2-week repetitive transcranial magnetic stimulation at the subacute phase of stroke (between day 7 and day 14) improves significantly arm motility at 3 months with remaining effect at one year, without significant adverse effect.

stroke survivors may be left with disability involving speech or residual arm or leg weakness. despite spontaneous improvement on the weeks following stroke, the importance of final disability is unpredictable. if the core of the infarct is represented by dead neurons, the neurons from adjacent areas seem to be staggered and their lack of excitability has been correlated to a bad prognosis. repetitive transcranial magnetic stimulation (rtms) seems to be a promising technique since high frequency rtms can increase excitability of the targeted neurons. the aim of the study is to evaluate after 2 weeks of 20 min of rtms each day: 1) the improvement of arm function and neurological and disability scales, immediately after the 2-week session, at one month, 3 months and evaluate the remnant effect at 12 months, 2) to correlate these scales to physiological parameters in order to assess the clinical modifications to the electrophysiological modifications, 3) to assert the safety of high frequency rtms at the subacute phase of ischaemic stroke.

Eligibility criteria:
inclusion criteria: single mono hemispheric subcortical and/or cortical ischaemic stroke (documented by ct or mri) 7 to 21 days before, with moderate arm paresis as defined by a rankin score \<= 4 or not at 4 (in paragraph 5 of nihss), in the territory of middle cerebral artery patients between 18 and 80 years old exclusion criteria: severe peripheral neuropathy pace-maker, implanted medical pump, metal plate, metal object in the skull or eye history of previous stroke, epileptic seizures, craniotomy, brain trauma score rankin \> 4 and arm deficit at 4 (paragraph 5 of nihss) score rankin \<=1 cortical stroke alertness problems at the time of inclusion disability previous to stroke stenosis of internal carotid artery with surgery foreseen within 3 months uncontrolled medical problem not able to give informed consent pregnant or breast-feeding woman

Keywords: rehabilitation transcranial magnetic stimulation brain magnetic stimulation repetitive stroke subacute
evaluation of 19-gauge vs 21-gauge ebus tbna in assessing thoracic lymphadenopathy

Conditions: Enlarged Lymph Nodes (Excluding Infective)

Summary: this study compares the yield of 19-gauge needles vs 21-gauge needles during ebus tbna procedures.

endobronchial ultrasound-guided transbronchial needle aspirate (ebus-tbna) is a technique used to take samples of body tissue inside the chest without having to undergo an operation. during this procedure, a special telescope (called a bronchoscope) is inserted through the mouth into the airways. ultrasound technology allows the doctor to see the structures just outside the airway. by being able to see the structures outside the airway, the doctor is able to safely pass a fine needle through the airway to take samples of abnormal tissue. ebus-tbna is used to take samples of tissue from the mediastinum. the mediastinum is the part of the chest between the lungs, and contains the heart, gullet, windpipe and lymph nodes. this area of the body is usually difficult to access without open surgery, hence the use of ebus-tbna. ebus-tbna may be used to investigate enlarged lymph nodes. this may be due to tuberculosis, sarcoidosis or cancer. currently, smaller 21-gauge and larger 19-gauge needles are used during the ebus-tbna procedure at regions hospital. the purpose of this study is to find out which needle is better in finding the explanation for the enlarged lymph nodes, and any follow up procedures that may be necessary if the investigators are unable to get enough tissue during the ebus-tbna procedure (surgical sampling, radiological sampling, and/or follow-up imaging).

Eligibility criteria:
inclusion criteria: * age 18 years or older * able to provide informed consent * referred for ebus tbna sampling at regions hospital exclusion criteria: * on therapeutic warfarin, plavix, or ticagrelor in the past 5 days * inr\>1.8 or platelets \<50k
a registry study of nanoknife ire for stage 3 pancreatic cancer

Conditions: Stage III Pancreatic Cancer

Summary: this multicenter, observational study will evaluate the effectiveness and safety of the nanoknife system when used for the ablation of stage 3 pancreatic adenocarcinoma (stage 3 pc). eligible patients will be recruited over a 36-month period and participating institutions will enroll and provide data on consecutive patients that meet inclusion and exclusion criteria. each patient will be followed up for the duration of the study or until death. the study will include two (2) cohorts: patients who received standard of care (soc) and received irreversible electroporation (ire) \[ire cohort\], and patients who were treated with soc and did not receive ire \[soc cohort\].


Eligibility criteria:
inclusion criteria: 1. provisions of signed and dated informed consent form 2. patient is 18 years of age and older 3. patient has a diagnosis of stage 3 pc cytologically or pathologically confirmed per american joint committee on cancer (ajcc) staging criteria 4. patient has a tumor evaluated as stage 3 according to national comprehensive cancer network (nccn) guidelines, based on radiographic imaging or exploratory surgery 5. maximum axial and anterior to posterior tumor dimension of ≤3.5cm after soc 6. patient has received 3 months of soc per each participating institution's guidelines 7. patient has an eastern cooperative oncology group (ecog) performance status of 0 or 1 8. patient has an american society of anesthesiologists (asa) classification of physical health status of 1 or 2. 9. patients at ire sites who are deemed eligible for ire and receive ablation using the nanoknife system 10. patient shows no evidence of disease progression based on nccn guidelines after completing three (3) months of soc exclusion criteria: 1. participation in an interventional trial for pancreatic cancer during the study data collection period 2. pregnant or lactating patients or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 6 months after the last dose of chemotherapy 3. patients who are unable to tolerate general anesthetic with full skeletal muscle blockade 4. patients with the presence of implanted cardiac pacemakers, defibrillators, electronic devices or implanted devices with metal parts in the thoracic cavity at the time of ire

Keywords: pancreas cancer pancreatic adenocarcinoma pancreatic ductal adenocarcinoma advanced pancreatic cancer carcinoma, pancreatic ductal locally advanced pancreatic cancer cancer of pancreas pancreatic tumor pancreatic carcinoma unresectable pancreatic cancer lapc
a safety, efficacy and pharmacokinetics study of cd11301 for the treatment of cutaneous t-cell lymphoma (ctcl)

Conditions: Cutaneous T Cell Lymphoma

Summary: to assess the efficacy, safety and pharmacokinetics in participants treated with cd11301 gel vs. placebo for early stage ctcl (ia, ib, or iia).

to assess the efficacy and safety of two concentrations (0.03% and 0.06%) of cd11301 gel in the treatment of early stage ctcl (stage ia, ib, or iia) versus placebo.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of ctcl stage ia, ib, or iia with biopsy within last 3 months * have bsa involvement corresponding to stages ia, ib or iia ctcl with at least 3 distinct lesions exclusion criteria: * ctcl that is stage iib or great or stage iia with stage n2 with \>5% circulating sezary cells or cd8+ or large cell transformation or progressive ctcl * history of autoimmune disease * laboratory test values at screening outside of the normal range and judged clinically significant by the investigator * current participation in another clinical trial of a drug or device or past participation within 4 weeks before baseline or participant is in exclusion period from a previous clinical trial

Keywords: t-cell lymphoma cutaneous ctcl
epidemiological study of out-of-hospital cardiac arrest in shenzhen

Conditions: Out-Of-Hospital Cardiac Arrest

Summary: the epidemiology of out-of-hospital cardiac arrest (ohca) is a significant public health issue, and large-sample studies on such events within china are relatively limited. this study utilizes the utstein model to evaluate and analyze the epidemiological characteristics of ohca in shenzhen from 2011 to 2018. by reviewing ambulance dispatch records and prehospital medical records from the shenzhen emergency medical center between 2011 and 2018, the study analyzed epidemiological characteristics and reported the results. the main indicators of the study include demographic characteristics such as the gender, age, location of occurrence, key time points, vital signs, chief complaints, and diagnoses of the cases. it also covers prehospital emergency treatment processes, including whether bystanders performed cpr, initial electrocardiogram results, intravenous access establishment, use of epinephrine, defibrillation, tracheal intubation, and other interventions, as well as the outcomes of resuscitation.


Eligibility criteria:
inclusion criteria: * cases with secondary diagnoses containing only the diagnostic keywords "cardiac arrest" and "sudden death" exclusion criteria: * 1. cases with suicide, drowning, advanced cancer, trauma, shock, poisoning, cerebrovascular accidents, etc. 2.cases with duplicate records for gender, age, time of call, pick-up and drop-off address, and initial diagnosis.
retrospective analysis of renal prognosis in patients with chronic kidney disease

Conditions: Diabetic Nephropathies; Lupus Nephritis; Rapidly Progressive Glomerulonephritis; Chronic Kidney Diseases

Summary: during 1993 and 2006, a total of 987 patients older than 20 years underwent native kidney biopsy at the renal division of this hospital. 404 patients with membranoproliferative glomerulonephritis and mesangioproliferative glomerulonephritis, and patients with secondary glomerulonephritis or other renal pathologies, such as diabetic nephropathy, lupus nephritis, rapid progress glomerulonephritis, acute tubular necrosis, and tubulointerstitial nephritis will be analyzed. the demographic characteristics and laboratory data of these patients at presentation or before renal biopsy will be recorded. these data included parameters such as age, sex, diabetes, hypertension, immunosuppressants treatment, bun, serum creatinine, albumin, hemoglobin, total cholesterol, triglycerides, and urine protein. all subjects will be followed until 2015 for occurrence of primary endpoints, including all-cause death or esrd requiring long-term dialysis or renal transplantation. a total of 433 patients who had been followed for 3 years during 2003 and 2007 will receive regular clinic follow-up. gfr will be estimated according to the modification of diet in renal disease (mdrd) abbreviated formula: 186 x scr -1.154 x age -0.203 x 0.742 (if female). ckd stage will be determined as described by the national kidney foundation of the united states. at the time of entry, gfrs of 30-59, 29-15 and \< 15 ml/min/1.73 m2 for more than 3 months will be classified as ckd stages 3, 4 and 5, respectively. baseline data of the 433 patients are used as recorded at the beginning during 2003 and 2007. the observation period of each patient is defined to start immediately after the registered measurement of serum creatinine satisfying the above criteria (designated as the index date) and lasted until esrd or end of 2015. esrd is defined as initiation of rrt, i.e. chronic dialysis or renal transplantation.


Eligibility criteria:
inclusion criteria : * patients older than 20 years. * patients underwent native kidney biopsy at the renal division of this hospital, and with renal pathologies, such as diabetic nephropathy, lupus nephritis, rapid progress glomerulonephritis. * patients were classified as ckd stages 3a, 3b, 4 and 5 at the time of entry. exclusion criteria : * patients younger than 20 years. * patients older than 20 years underwent native kidney biopsy at the renal division of this hospital, and with renal pathologies, such as membranoproliferative glomerulonephritis, mesangioproliferative glomerulonephritis, secondary glomerulonephritis, or other renal pathologies, such as, acute tubular necrosis, and tubulointerstitial nephritis. * patients older than 20 years but egfr ≧ 60 ml/min/1.73 m2 at the time of entry.

Keywords: renal biopsy, chronic kidney disease,diabetic nephropathy,lupus nephritis
the effect of fecal microbiota transplantation in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: 7 patients with active ulcerative colitis are treated with 25 multi-donor fmt capsules daily for 50 days.

7 patients with active ulcerative colitis are treated with 25 multi-donor fmt capsules daily for 50 days all patients are followed with regular follow up after 2,4,8,12,16, 20 and 24 weeks.

Eligibility criteria:
inclusion criteria: * diagnosed with ulcerative colitis (uc) * sccai between 4 and 10 at inclusion * on a stable dose of 5-aminosalicylic acid (5-asa) or without current treatment. * previous treatment with glucocorticoids, thiopurines and/or biological treatment was accepted. * fecal calprotectin \> 250 mg/kg * colonoscopy performed within the last 3 years * capable of writing and speaking danish * attending regular follow-ups by a specialist in gastroenterology. exclusion criteria: * biological treatment within the last four weeks * treatment with antibiotics within 48 hours before intervention * alcohol use above current danish guidelines (14 units/week for men and 7 units/week for women) * pregnancy or planned pregnancy * active cancer disease * medical treatment of mental disorder * other chronic gastroenterological disorder besides uc, irritable bowel syndrome (ibs) or reflux-disease.

Keywords: fecal microbiota transplantation
tissue-specific metabolic reprogramming in diabetic complications

Conditions: Type 1 Diabetes Mellitus

Summary: we will perform blood sugar studies to assess changes in metabolic (biochemical processes that occur within us) profiles associated with high blood sugar and diabetes.

objective: to assess steady state and dynamic metabolite changes in subjects with type 1 diabetes with and without microvascular complications and to understand intrinsic differences from non-diabetics in metabolite levels and flux. the hypothesis is that diabetic complications arise from tissue-specific metabolic reprogramming resulting in alterations in fuel utilization which lead to dysfunction of the tissue. to test this hypothesis, we will use sensitive and specific mass spectrometer based metabolomic analysis to measure steady state metabolite levels in plasma and urine from controls subjects and subjects with t1dm, without and with diabetic complications during euglycemic and hyperglycemic clamp studies.

Eligibility criteria:
group 1: t1dm subjects without complications: group 2: t1dm subjects with microalbuminuria . group 3: t1dm subjects with advanced diabetes complications group 4: age-and-sex-matched healthy control subjects . inclusion criteria: general entry criteria: must have type 1 diabetes \> 5 years duration. 18 years of age or older subjects in the microalbuminuria group will have a history of urinary microalbumin to creatinine ration between 30-300 m/g confirmed on repeat testing while the non-albuminuric group will have a value of less than 30 mg/g. subjects in advanced complications group will have confirmed retinopathy, peripheral and/or autonomic neuropathy and nephropathy. non diabetic individuals will be matched for age and gender and will have normal glucose tolerance, normal lipid metabolism, and normal blood pressure. exclusion criteria: age less than 18 . women of child-bearing potential who may be pregnant or lactating history of pancreas, kidney or liver transplant history of drug or alcohol use. history of cancer other than basal cell carcinoma or squamous cell skin cancer. presence of a condition that in the opinion of the investigator would make it unlikely for the subject to complete the study. -
repetitive transcranial magnetic stimulation with h-coil in alzheimer's disease

Conditions: Alzheimer Disease

Summary: focal repetitive transcranial magnetic stimulation (rtms) has been applied to improve cognition in alzheimer's disease (ad) with conflicting results. in this study we aimed to explore feasibility, safety and efficacy of excitatory rtms of bilateral dlpfc applied with h-coil in ad in a pilot randomized, placebo-controlled, double-blind study.

study design the study was a double-blind, placebo-controlled paradigm, with randomization into a real rtms group or a sham rtms

Eligibility criteria:
inclusion criteria: * ability to understand the purpose and risk of the study and provide signed and dated informed consent. * male or female subjects, 18 to 80 years old. * diagnosis of alzheimer's disease according to the dsm iv * subjects who answered all questions in the tms pre-treatment safety questionnaire in a negative manner. * have given written informed consent exclusion criteria: * presence of an additional neurological or psychiatric pathology. * severe personality disorder. * uncontrolled hypertension. * history of epilepsy, seizures, febrile convulsions. * history of epilepsy or seizures in first degree relatives. * history of head injury or stroke. * presence of metal prostheses in the head (except dental fillings). * metal implants or known history of any metal particles in the eye, cardiac pacemakers, cochlear implants, use of neurostimulators or medical pumps. * history of migraine within the past six months. * history of drug or alcohol abuse. * impossibility of adequate communication with the examiner. * participation in another clinical study, either concomitant or within the previous 3 months. * inability to sign the consent form.